Albireo Pharma (DB:BDQM) - Stock Price, News & Analysis

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

BDQM Stock Overview

About the company

BDQM fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Revenue is forecast to grow 51.41% per year

Risk Analysis

Highly volatile share price over the past 3 months

Currently unprofitable and not forecast to become profitable over the next 3 years

Shareholders have been diluted in the past year

Albireo Pharma, Inc. Competitors

Formycon

XTRA:FYB

€709.9m

MorphoSys

XTRA:MOR

€2.6b

Biotest

XTRA:BIO3

€1.4b

Heidelberg Pharma

XTRA:HPHA

€138.0m

Price History & Performance

Summary of all time highs, changes and price drops for Albireo Pharma
Historical stock prices
Current Share Price	US$41.41
52 Week High	US$42.05
52 Week Low	US$16.11
Beta	1.04
1 Month Change	2.25%
3 Month Change	83.80%
1 Year Change	72.25%
3 Year Change	114.12%
5 Year Change	52.02%
Change since IPO	153.77%

Recent updates

Shareholder Returns

	BDQM	DE Biotechs	DE Market
7D	0.3%	-4.3%	-2.5%
1Y	72.3%	-19.4%	-0.4%

Return vs Industry: BDQM exceeded the German Biotechs industry which returned 7.3% over the past year.

Return vs Market: BDQM exceeded the German Market which returned -6.2% over the past year.

Price Volatility

Is BDQM's price volatile compared to industry and market?
BDQM volatility
BDQM Average Weekly Movement	26.5%
Biotechs Industry Average Movement	5.0%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	9.9%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: BDQM's share price has been volatile over the past 3 months.

Volatility Over Time: BDQM's weekly volatility has increased from 16% to 26% over the past year.

About the Company

Founded	Employees	CEO	Website
n/a	130	Ron Cooper	www.albireopharma.com

Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children; and Elobixibat for the treatment of chronic constipation and other functional diseases. It also engages in the developing of A3907, which is in Phase I clinical trial for the treatment of adult liver diseases; and A2342, a preclinical candidate to treat adult viral and liver diseases.

Albireo Pharma, Inc. Fundamentals Summary

How do Albireo Pharma's earnings and revenue compare to its market cap?
BDQM fundamental statistics
Market cap	€869.09m
Earnings (TTM)	-€123.74m
Revenue (TTM)	€54.15m

16.1x

P/S Ratio

-7.0x

P/E Ratio

Is BDQM overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BDQM income statement (TTM)
Revenue	US$57.39m
Cost of Revenue	US$2.55m
Gross Profit	US$54.84m
Other Expenses	US$185.99m
Earnings	-US$131.14m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	-6.29
Gross Margin	95.56%
Net Profit Margin	-228.51%
Debt/Equity Ratio	0%

How did BDQM perform over the long term?

See historical performance and comparison

This company listing is no longer active

BDQM Stock Overview

Rewards

Risk Analysis

Albireo Pharma, Inc. Competitors

XTRA:FYB

€709.9m

XTRA:MOR

€2.6b

XTRA:BIO3

€1.4b

XTRA:HPHA

€138.0m

Price History & Performance

Recent News & Updates

Forecast to breakeven in 2025

Albireo Pharma, Inc. Announces U.S. Food and Drug Administration Accept Its Supplemental New Drug Application

Ipsen Biopharmaceuticals, Inc. entered into a definitive merger agreement to acquire Albireo Pharma, Inc. (NasdaqCM:ALBO) for approximately $910 million.

Ipsen Biopharmaceuticals, Inc. entered into a definitive merger agreement to acquire Albireo Pharma, Inc. (NasdaqCM:ALBO) for approximately $910 million.

Ipsen S.A. (ENXTPA:IPN) entered into a definitive merger agreement to acquire Albireo Pharma, Inc. (NasdaqCM:ALBO) for approximately $870 million.

Albireo Pharma, Inc. Submits Bylvay(R) Alagille Syndrome Regulatory Filings to FDA and EMA

Recent updates

Forecast to breakeven in 2025

Albireo Pharma, Inc. Announces U.S. Food and Drug Administration Accept Its Supplemental New Drug Application

Ipsen Biopharmaceuticals, Inc. entered into a definitive merger agreement to acquire Albireo Pharma, Inc. (NasdaqCM:ALBO) for approximately $910 million.

Ipsen Biopharmaceuticals, Inc. entered into a definitive merger agreement to acquire Albireo Pharma, Inc. (NasdaqCM:ALBO) for approximately $910 million.

Ipsen S.A. (ENXTPA:IPN) entered into a definitive merger agreement to acquire Albireo Pharma, Inc. (NasdaqCM:ALBO) for approximately $870 million.

Albireo Pharma, Inc. Submits Bylvay(R) Alagille Syndrome Regulatory Filings to FDA and EMA

Albireo Pharma, Inc. Appoints Paul Streck as Chief Medical Officer and Craig Hopkinson to its Board of Directors

Third quarter 2022 earnings released: US$1.92 loss per share (vs US$2.96 profit in 3Q 2021)

Albireo Pharma, Inc. Presents New Data at the American Association for the Study of Liver Diseases

Albireo Pharma, Inc. Completes Phase 3 BOLD Study Enrollment of Bylvay(R) in Biliary Atresia

Albireo Pharma, Inc. to Present Late Breaking Bylvay (odevixibat) Data at AASLD 2022

Albireo Pharma, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Albireo Pharma, Inc. Reports Positive Topline Data from Phase 3 Trial of Bylvay® (Odevixibat) in Alagille Syndrome

Albireo to Showcase New Data at AASLD The Liver Meeting® 2022

No longer forecast to breakeven

Albireo Pharma, Inc. Announces Enabled Reimbursed Access to Bylvay for the Treatment of All Types of Progressive Familial Intrahepatic Cholestasis Patients in Italy

Albireo Pharma, Inc. Announces New Committee Member Appointments

Second quarter 2022 earnings released: US$2.04 loss per share (vs US$1.90 loss in 2Q 2021)

No longer forecast to breakeven

Albireo Pharma, Inc. Announces the Appointments of Habib Dable and Susan Alesina to its Board of Directors

Albireo Pharma, Inc. to Report Q2, 2022 Results on Aug 15, 2022

Albireo Pharma, Inc. Announces Lancet Gastroenterology & Hepatology Published the Results of the Pivotal PEDFIC 1 Trial

Albireo Pharma, Inc.(NasdaqCM:ALBO) dropped from Russell Microcap Value Index

Albireo Presents New Bylvay® (odevixibat) Data at Annual ESPGHAN Congress

Albireo Pharma, Inc. Announces Presentation of New Data in Pediatric and Adult Liver Diseases

Albireo Pharma, Inc. Provides Sales Guidance for the Year 2022

First quarter 2022 earnings released: US$2.19 loss per share (vs US$2.29 loss in 1Q 2021)

Albireo Pharma, Inc. to Report Q1, 2022 Results on May 16, 2022

Insufficient new directors

Albireo Pharma, Inc., Annual General Meeting, Jun 16, 2022

Albireo Completes Enrollment in Pivotal Phase 3 ASSERT Study of BylvayTM (odevixibat) in Alagille Syndrome

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Albireo Pharma, Inc. Announces Publication of the PICTURE Study Highlighting the Caregiver Impact of PFIC, a Rare and Devastating Children’s Liver Disease

Forecast to breakeven in 2024

Albireo Announces Positive Topline Data from Phase 1 Study of A3907

Albireo Pharma, Inc. Presenting New Bylvay™ (Odevixibat) Data at NASPGHAN 2021

Third quarter 2021 earnings released: EPS US$2.96 (vs US$1.96 loss in 3Q 2020)

Albireo Pharma, Inc. Receives UK MHRA Approval of Bylvay® (odevixibat)

Second quarter 2021 earnings released: US$1.90 loss per share (vs US$1.38 loss in 2Q 2020)

Albireo Pharma, Inc. Announces European Commission Authorization of Bylvay (Odevixibat), the First Drug Approved for the Treatment of All Subtypes of Progressive Familial Intrahepatic Cholestasis

Albireo Pharma, Inc. Announces Expanded Phase 3 Data on Bylvay™ (odevixibat) and A3907 at Upcoming Easl International Liver Congress

Albireo Pharma, Inc Presents Clinical Data from Its Phase 3 Pedfic 1 Study and an Interim Data Cut of the Pedfic 2 Long-Term Extension Study of Its Lead Product Candidate, Bylvay

Albireo Receives Positive CHMP Opinion for Bylvay™ (odevixibat) for Treatment of Progressive Familial Intrahepatic Cholestasis (PFIC)

Albireo Pharma, Inc. Announces the Presentation of New Data from its Phase 3 PEDFIC 1 Study and PEDFIC 2 Long-Term Extension Study of its Lead Product Candidate, Bylvay

First quarter 2021 earnings released: US$2.29 loss per share (vs US$2.23 loss in 1Q 2020)

New 90-day low: €27.62

Full year 2020 earnings released: US$6.73 loss per share (vs US$5.04 loss in FY 2019)

Revenue beats expectations

Albireo Pharma, Inc. to Report Q4, 2020 Results on Feb 25, 2021

New 90-day high: €34.76

Albireo Announces U.S. Fda Acceptance of New Drug Application for Odevixibat

Albireo Pharma, Inc. Initiates Global Phase 3 Clinical Trial of Odevixibat in Alagille Syndrome

New 90-day high: €33.98

Albireo Pharma, Inc. Submits for U.S. FDA and EMA Product Approval of Once-Daily Odevixibat for PFIC

Albireo Pharma, Inc. Announce New Phase 3 Data at AASLD Show Durable Response to Odevixibat in a Rare Pediatric Liver Disease

Third quarter 2020 earnings released: US$1.96 loss per share

Revenue beats expectations

Albireo Pharma, Inc.’s Odevixibat PFIC Phase 3 Results Accepted for AASLD Late-Breakers